Laguna Bio is an IND-ready company that makes immunotherapy effective for everyone. We've developed a live bacterial therapeutic that activates and expands endogenous gamma delta T cells. These cells have been shown to have efficacy against heme malignancies, and we believe that they can significantly improve the efficacy of all CD3-engaging bispecific antibodies. The foundation of our approach was proven to be safe in over 500 cancer patients through previous clinical studies, and the immune cell activation and expansion has been validated in cancer patients as well. Our lead candidate will be a differentiator for the BCMA/CD3 bispecific antibody landscape. We are planning to initiate a series A raise at the end of September to fund our first clinical study initiating in 1H24.